Article
New Survey Finds 55% of Radiologists Have Concerns About Contrast Agent Availability
Bracco Diagnostics Inc. releases data from 200 radiologists on the current state of their field
Article
Leaders on the Horizon
The Bracco-Supported Applied Radiology Residency Program that champions the next generation of radiology leaders
Page
Unique Device Identification
To comply with the U.S. Food and Drug Administration ruling on Unique Device Identification (UDI) and improve supply chain efficiency, Bracco Diagnostics is transitioning to a GS1 compliant barcode.
Page
Gadopiclenol
This webpage on GADOPICLENOL provides an informative overview of the new FDA approved contrast-agent. This page is an informative and unbranded resource for anyone interested in learning more about GADOPICLENOL news and press releases.
Page
Product
Quantification software
VueBox® is a Bracco-patented, general-purpose software application for quantifying tissue perfusion using Dynamic Contrast-Enhanced Ultrasound (DCE-US).
Article
ACR Classifies Gadopiclenol as a Group II Agent
Gadopiclenol solution for injection and Gadopiclenol Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 2023.
Article
BRACCO INVITES YOU @ RSNA 2023
Bracco Diagnostics Showcases Innovation and Collaborative Vision at RSNA 2023 Annual Meeting.
Article
Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology
The results of the multicenter, international PROMISE clinical trial demonstrate that gadopiclenol provides similar lesion visualization and contrast enhancement at a gadolinium dose of 0.05 mmol/kg versus a full dose of gadobutrol (0.1 mmol/kg).
Article
Funding the Future of Radiology¹
With an over $1.8 million investment in radiology research, Bracco Diagnostics Inc. actively supports the advancement of the field by ensuring that 34 early-career radiological investigators have access to much-needed funding.